In the British pharmaceutical industry, there were 26 M&A deals announced in Q2 2023, worth a total value of $6.9bn, according to GlobalData’s Deals Database. The $6.1bn acquisition of dechra pharmaceuticals by freya bidco was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes, the M&A activity and most notable deals are included in GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, M&A activity in The UK increased by 306% in Q2 2023 compared with the previous quarter’s total of $1.7bn and rose by 455% as compared to Q2 2022. Related deal volume increased by 37% in Q2 2023 versus the previous quarter and was 63% higher than in Q2 2022.
The top-ranked financial advisors supporting these M&A deals in The UK in Q2 2023 were Investec; Canaccord Genuity Group; Cap Equity Advisors with 2, 1, 1 deals respectively.
The top-ranked legal advisorss supporting these M&A deals in The UK Q2 2023 were DLA Piper; Addleshaw Goddard; Ashurst with 3, 2, 2 deals respectively.
For further understanding of GlobalData's Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.